Beta2-microglobulin predicts survival in primary systemic amyloidosis

Morie Gertz, Robert A. Kyle, Philip R. Greipp, Jerry A. Katzmann, W. Michael O'Fallon

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

purpose: The study assessed whether β2-microglobulin levels predict survival or response in patients with primary systemic amyloidosis without associated multiple myeloma. patients and methods: The study group consisted of 131 untreated patients with biopsy-proven primary systemic amyloidosis diagnosed and evaluated at the Mayo Clinic. No patient had multiple myeloma. The minimum follow-up of surviving patients is 8 years. No patient was lost to follow-up. results: The median survival of patients with an increased β2-microglobulin level was 10.8 months, compared with patients with a normal β2-microglobulin level (less than or equal to 2.7 μg/mL, 0.23 μmol/L) of 32.9 months (p <0.001). In a multivariate proportional-hazards model, the best model included congestive heart failure (p <0.0001) and increased β2-microglobulin levels (p <0.05). After adjustment for the presence of congestive heart failure, β2-microglobulin level remained significant. When the analysis was restricted to those patients with normal renal function, the median survival of those with an elevated β2-microglobulin level was 9.1 months versus 39.4 months for those with a normal level (p <0.001). The serum level of β2-microglobulin was increased in patients with nephrotic-range proteinuria with or without renal insufficiency (p = 0.05). conclusion: The serum β2-microglobulin level should be measured routinely in all patients with primary systemic amyloidosis because it provides a useful objective factor to identify subsets of patients with this disease who have unfavorable outcomes.

Original languageEnglish (US)
Pages (from-to)609-614
Number of pages6
JournalThe American journal of medicine
Volume89
Issue number5
DOIs
StatePublished - Jan 1 1990

Fingerprint

Survival
Multiple Myeloma
Primary amyloidosis
Heart Failure
Lost to Follow-Up
Serum
Proteinuria
Proportional Hazards Models
Renal Insufficiency
Kidney
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Beta2-microglobulin predicts survival in primary systemic amyloidosis. / Gertz, Morie; Kyle, Robert A.; Greipp, Philip R.; Katzmann, Jerry A.; O'Fallon, W. Michael.

In: The American journal of medicine, Vol. 89, No. 5, 01.01.1990, p. 609-614.

Research output: Contribution to journalArticle

Gertz, Morie ; Kyle, Robert A. ; Greipp, Philip R. ; Katzmann, Jerry A. ; O'Fallon, W. Michael. / Beta2-microglobulin predicts survival in primary systemic amyloidosis. In: The American journal of medicine. 1990 ; Vol. 89, No. 5. pp. 609-614.
@article{7b5d01b17ecc458cafeba39d03bc7b33,
title = "Beta2-microglobulin predicts survival in primary systemic amyloidosis",
abstract = "purpose: The study assessed whether β2-microglobulin levels predict survival or response in patients with primary systemic amyloidosis without associated multiple myeloma. patients and methods: The study group consisted of 131 untreated patients with biopsy-proven primary systemic amyloidosis diagnosed and evaluated at the Mayo Clinic. No patient had multiple myeloma. The minimum follow-up of surviving patients is 8 years. No patient was lost to follow-up. results: The median survival of patients with an increased β2-microglobulin level was 10.8 months, compared with patients with a normal β2-microglobulin level (less than or equal to 2.7 μg/mL, 0.23 μmol/L) of 32.9 months (p <0.001). In a multivariate proportional-hazards model, the best model included congestive heart failure (p <0.0001) and increased β2-microglobulin levels (p <0.05). After adjustment for the presence of congestive heart failure, β2-microglobulin level remained significant. When the analysis was restricted to those patients with normal renal function, the median survival of those with an elevated β2-microglobulin level was 9.1 months versus 39.4 months for those with a normal level (p <0.001). The serum level of β2-microglobulin was increased in patients with nephrotic-range proteinuria with or without renal insufficiency (p = 0.05). conclusion: The serum β2-microglobulin level should be measured routinely in all patients with primary systemic amyloidosis because it provides a useful objective factor to identify subsets of patients with this disease who have unfavorable outcomes.",
author = "Morie Gertz and Kyle, {Robert A.} and Greipp, {Philip R.} and Katzmann, {Jerry A.} and O'Fallon, {W. Michael}",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/0002-9343(90)90179-H",
language = "English (US)",
volume = "89",
pages = "609--614",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Beta2-microglobulin predicts survival in primary systemic amyloidosis

AU - Gertz, Morie

AU - Kyle, Robert A.

AU - Greipp, Philip R.

AU - Katzmann, Jerry A.

AU - O'Fallon, W. Michael

PY - 1990/1/1

Y1 - 1990/1/1

N2 - purpose: The study assessed whether β2-microglobulin levels predict survival or response in patients with primary systemic amyloidosis without associated multiple myeloma. patients and methods: The study group consisted of 131 untreated patients with biopsy-proven primary systemic amyloidosis diagnosed and evaluated at the Mayo Clinic. No patient had multiple myeloma. The minimum follow-up of surviving patients is 8 years. No patient was lost to follow-up. results: The median survival of patients with an increased β2-microglobulin level was 10.8 months, compared with patients with a normal β2-microglobulin level (less than or equal to 2.7 μg/mL, 0.23 μmol/L) of 32.9 months (p <0.001). In a multivariate proportional-hazards model, the best model included congestive heart failure (p <0.0001) and increased β2-microglobulin levels (p <0.05). After adjustment for the presence of congestive heart failure, β2-microglobulin level remained significant. When the analysis was restricted to those patients with normal renal function, the median survival of those with an elevated β2-microglobulin level was 9.1 months versus 39.4 months for those with a normal level (p <0.001). The serum level of β2-microglobulin was increased in patients with nephrotic-range proteinuria with or without renal insufficiency (p = 0.05). conclusion: The serum β2-microglobulin level should be measured routinely in all patients with primary systemic amyloidosis because it provides a useful objective factor to identify subsets of patients with this disease who have unfavorable outcomes.

AB - purpose: The study assessed whether β2-microglobulin levels predict survival or response in patients with primary systemic amyloidosis without associated multiple myeloma. patients and methods: The study group consisted of 131 untreated patients with biopsy-proven primary systemic amyloidosis diagnosed and evaluated at the Mayo Clinic. No patient had multiple myeloma. The minimum follow-up of surviving patients is 8 years. No patient was lost to follow-up. results: The median survival of patients with an increased β2-microglobulin level was 10.8 months, compared with patients with a normal β2-microglobulin level (less than or equal to 2.7 μg/mL, 0.23 μmol/L) of 32.9 months (p <0.001). In a multivariate proportional-hazards model, the best model included congestive heart failure (p <0.0001) and increased β2-microglobulin levels (p <0.05). After adjustment for the presence of congestive heart failure, β2-microglobulin level remained significant. When the analysis was restricted to those patients with normal renal function, the median survival of those with an elevated β2-microglobulin level was 9.1 months versus 39.4 months for those with a normal level (p <0.001). The serum level of β2-microglobulin was increased in patients with nephrotic-range proteinuria with or without renal insufficiency (p = 0.05). conclusion: The serum β2-microglobulin level should be measured routinely in all patients with primary systemic amyloidosis because it provides a useful objective factor to identify subsets of patients with this disease who have unfavorable outcomes.

UR - http://www.scopus.com/inward/record.url?scp=0025026361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025026361&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(90)90179-H

DO - 10.1016/0002-9343(90)90179-H

M3 - Article

VL - 89

SP - 609

EP - 614

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5

ER -